OneSource Pharma Eyes Obesity Drug Growth, Expansion

  Published 9 months ago

OneSource Pharma anticipates strong growth from obesity drugs as semaglutide patents expire in 2026, driving new orders and expansion plans.

  • Added 15 obesity/diabetes drug orders in FY2025, with more in pipeline and 30% CAGR expected through FY2028.
  • Competes with Piramal, Divi's; invests $100M to expand drug, device facilities and global manufacturing footprint.
  • Demerged from Strides in January, aiming for U.S. and Europe manufacturing presence post-listing.

You might like these

Tata Acquires ES‑Tec, Expands ADAS Reach

Muthoot Finance Surpasses 1 Trillion Market Cap

Insolation Energy Secures 109.79 MW Solar Project in Rajasthan

Poonawalla Fincorp Leverages AI for Growth

Gland Pharma Q1 Profit Jumps 43%

Trump Doubles Steel Tariffs: Trade War Escalates

Navodaya Vidyalaya Samiti's Major Campus Projects

News that matters the most ⚡